Signet Financial Management
BIB icon

Signet Financial Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Signet Financial Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$16K – 370
2021
Q4 		$16K Buy
+200
New +$17.1K ﹤0.01% 929

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
Old Mission Capital
Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Jump Financial
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
Traynor Capital Management
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Signet Financial Management's BIB Position: Q1 2022 in Review

Signet Financial Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2022, closing a stake of 200 shares — an estimated $16K sold.

Signet Financial Management first reported a position in BIB in Q4 2021 and held it in 1 quarter. The position peaked at $16K in Q4 2021. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2022.

  • Signet Financial Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 200 ProShares Ultra NASDAQ Biotechnology shares in Q1 2022, an estimated $16K.
  • Signet Financial Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's ProShares Ultra NASDAQ Biotechnology position peaked at $16K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.